Users blast availability of MedGuides

Share this article:
The FDA's Medication Guide (MedGuide) program was the object of intense criticism from reps of retail pharmacy organizations, consumer groups and academic researchers at a public hearing by the agency in June.

Congressman Michael Ferguson (R-NJ), expressed concern that, although the FDA has authority to require manufacturers to provide MedGuides for selected products, monitoring to assure they are available at pharmacies is largely left to individual state pharmacy boards. He was skeptical that pharmacy boards in every state are assuring compliance or, in some cases, are even aware of their responsibilities in this area. Ferguson urged FDA to grant more “flexibility” in acceptable MedGuide formats and he strongly endorsed the concept of e-distribution.

E-distribution proposals were also endorsed by Tom Lawlor, an executive with the Walgreen Company.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.